All In Biotech

Drug Trial Radar · NCT07446491

A Study to Evaluate the Safety and Efficacy of PN20 in the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing an Elective Procedure

A Phase Ib/II Clinical Study to Evaluate the Efficacy, Safety, Pharmacokinetic and Pharmacodynamic Characteristics of a Single Subcutaneous Injection of Polyethylene Glycolated Thrombopoietin Peptide (PN20) in the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing an Elective Procedure

Last checked: Nov 19, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

54

Actual

Start

Jun 6, 2025

Primary completion

Oct 10, 2026

Study completion Oct 15, 2026

Sponsor

Sponsor type
Industry
First posted
Mar 3, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main aim of this clinical trial is to assess the safety and efficacy of a single dose of PN20 in treatment of thrombocytopenia in adult patients with chronic liver disease undergoing an elective procedure. The main questions it aims to answer are: * How effective is PN20 in treating thrombocytopenia in patients with chronic liver disease? * Is PN20 safe in these patients? Participants will * Receive a single subcutaneous injections of PN20 or placebo according to weight before an elective procedure, * Visit the clinic for assessment.

Conditions

  • Thrombocytopenia Associated With Chronic Liver Disease

Interventions

  • PN20Drug

    subcutaneous injection

  • PlaceboDrug

    subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The proportion of respondersTime frame: 8 days (from 24 hours pre-surgery through 7 days post-surgery)

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • Capital Medical University Affiliated Beijing Ditan Hospital

    Beijing, Beijing Municipality, China

  • The Second Affiliated Hospital of Chongqing Medical University

    Chongqing, Chongqing Municipality, China

  • The Eighth Affiliated Hospital of Guangzhou Medical University

    Guangzhou, Guangdong, China

  • Henan Provincial People's Hospital

    Zhengzhou, Henan, China

  • Zhenjiang Third People's Hospital

    Zhenjiang, Jiangsu, China

  • Jilin University First Hospital

    Changchun, Jilin, China

  • Liaocheng People's Hospital

    Chaozhou, Shandong, China

  • Qingdao Municipal Hospital

    Qingdao, Shandong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.